RCKT Q2 2024 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$2M

Operating Income

-$74M

Net Income

-$70M

EPS (Diluted)

$-0.74

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$56M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$446M

Total Liabilities

$62M

Stockholders' Equity

$385M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$2M	$0	—
Operating Income	-$74M	-$69M	-7.2%
Net Income	-$70M	-$66M	-6.0%